SCHEMBL2008301

SCHEMBL2008301

Oc1ccc2[nH]cnc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPK14 Q16539 1/20 0.41
CDK2 P24941 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HSD11B1 P28845 2/20 0.35
PKM P14618 1/20 0.35
CTSA P10619 2/20 0.35
PAK1 Q13153 1/20 0.34
CCNT1 O60563 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050731 0.76 ALDH1A1 (0.44) ALDH1A1KDM4ELMNAMEN1POLB
SCHEMBL29424771 0.76 ALDH1A1 (0.44) ALDH1A1KDM4ELMNAMEN1POLB
SCHEMBL29804853 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAMAPK14CDK2
SCHEMBL30343120 0.76 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAMAPK14CDK2
SCHEMBL14930380 0.76 ALDH1A1 (0.44) ALDH1A1KDM4ELMNAKMT2AMAPK14
SCHEMBL2105191 0.76 KDM4E (0.53) ALDH1A1KDM4ELMNAMAPK14CDK2
SCHEMBL3180578 0.76 ALDH1A1 (0.53) ALDH1A1KDM4ELMNAMAPK14CDK2
SCHEMBL2008297 0.76 ALDH1A1 (0.44) ALDH1A1KDM4ELMNAMEN1POLB
SCHEMBL1896584 0.74 KDM4E (0.47) ALDH1A1KDM4ELMNAMEN1KMT2A
SCHEMBL1806681 0.72 HSD11B1 (0.44) ALDH1A1KDM4EKMT2AMAPK14CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3341731-A1 METHOD FOR IDENTIFYING A COMPOUND USEFUL IN MITIGATING AND/OR THE TREATMENT OF A DISEASE ASSOCIATED WITH ABNORMAL ASTROCYTIC FUNCTION Celica BIOMEDICAL (SI) 2018-07-04 EP claimed
WO-2017060367-A1 METHOD FOR IDENTIFYING A COMPOUND USEFUL IN MITIGATING AND/OR THE TREATMENT OF A DISEASE ASSOCIATED WITH ABNORMAL ASTROCYTIC FUNCTION CELICA BIOMEDICAL (SI) 2017-04-13 WO claimed
EP-0184738-A2 Imidazole derivatives, medicaments containing these compounds, and process for their preparation Dr. Karl Thomae GmbH (DE) 1986-06-18 EP claimed
EP-3444238-B1 PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS SATO PHARMA (JP) 2021-12-08 EP disclosed
EP-3444238-A2 PROCESS FOR PREPARING DIFLUOROMETHYLENE COMPOUNDS Sato Pharmaceutical Co., Ltd. (JP) 2019-02-20 EP disclosed
EP-2878594-B1 DIFLUOROMETHYLENE COMPOUND SATO PHARMA (JP) 2018-11-28 EP disclosed
EP-3341731-A1 METHOD FOR IDENTIFYING A COMPOUND USEFUL IN MITIGATING AND/OR THE TREATMENT OF A DISEASE ASSOCIATED WITH ABNORMAL ASTROCYTIC FUNCTION Celica BIOMEDICAL (SI) 2018-07-04 EP disclosed
US-9650380-B2 Difluoromethylene compound SATO PHARMACEUTICAL CO., LTD. (JP) 2017-05-16 US disclosed
WO-2017060367-A1 METHOD FOR IDENTIFYING A COMPOUND USEFUL IN MITIGATING AND/OR THE TREATMENT OF A DISEASE ASSOCIATED WITH ABNORMAL ASTROCYTIC FUNCTION CELICA BIOMEDICAL (SI) 2017-04-13 WO disclosed
US-20170044158-A1 DIFLUOROMETHYLENE COMPOUND SATO PHARMACEUTICAL CO., LTD. (JP) 2017-02-16 US disclosed
US-9512119-B2 Difluoromethylene compound SATO PHARMACEUTICAL CO., LTD. (JP) 2016-12-06 US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
US-20080275069-A1 Quinazoline Derivative MSD K.K. (JP) 2008-11-06 US disclosed
EP-1944301-A1 NOVEL BENZOXATHIIN DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-07-16 EP disclosed
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative MSD K.K. (JP) 2007-07-19 US disclosed
EP-1757594-A1 QUINAZOLINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-02-28 EP disclosed
EP-1719756-A1 NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed
EP-0184738-A2 Imidazole derivatives, medicaments containing these compounds, and process for their preparation Dr. Karl Thomae GmbH (DE) 1986-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044158-A1 DIFLUOROMETHYLENE COMPOUND XDH, URB2, MNAT1 ALDH1A1 271/4885KDM4E 1780/4885LMNA 2671/4885
US-20080275069-A1 Quinazoline Derivative HRH3, HRH4, HRH2 ALDH1A1 2782/4885KDM4E 3385/4885LMNA 4491/4885
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 ALDH1A1 1717/4885KDM4E 1674/4885LMNA 4856/4885
US-20070167453-A1 Nitrogenous fused heteroaromatic ring derivative HRH3, HRH2, HRH4 ALDH1A1 1934/4885KDM4E 4024/4885LMNA 4522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.